19th Annual Scientific Meeting
15 – 17 February, 2023 // Washington, DC
Distinguished Poster Award Recipient:
|
|||
|
Latency distributions in speech during structured psychiatric interviews of patients with bipolar depression: automated speech analysis may provide a simple cognitive biomarker (abstract) – Hopkins |
|||
|
All Poster PDFs and Abstracts are available here. |
|||
15 February 2023 |
|||
| Welcome from the President | Gary Sachs slides video |
||
| Andrew C. Leon Distinguished Career Award Presentation | Gary Sachs Ramy Mahmoud slidesLarry Ereshefsky slides video |
||
| From Real World Data to Real World Evidence – Implementation of regulatory guidance in drug development | Chairs: Michael Davis Ibrahim Turkoz |
||
| Introduction
|
Michael Davis slides video |
||
| FDA’s Real World Evidence program | John Concato slides video |
||
| Real World Evidence: PDUFA VII commitments and FDA use cases | Motiur Rahman slides video |
||
| Gathering and use of RWE in a European setting | Karl Broich slides video |
||
| Recruitment strategy for prospective observational studies to mimic randomization: Up-front matching | Ibrahim Turkoz slides video |
||
| Enhancing CNS product labels with pragmatic trials: Challenges, solutions, and outcomes that support the road to RWE | Larry Alphs slides video |
||
| Panel Discussion | Facilitators: Michael Davis Ibrahim Turkoz Discussants: Samuel Wilkinson slidesAndrew Potter slides video |
||
|
Wednesday Working Group Sessions |
|||
| Behavioral and Psychiatric Symptoms in Dementia (BPSD) Apathy Working Group | Chairs: Krista Lanctôt David Miller summary |
||
| Estimands and Missing Data Working Group | Chair: Elena Polverejan summary |
||
| Negative Symptoms Working Group | Chairs: David Daniel Stephen Marder summary |
||
| Orphan Diseases Working Group | Chairs: Joan Busner Gahan Pandina slides |
||
16 February 2023 |
|||
| Lewis Alan Opler Prize Presentation | Gary Sachs slidesSøren Østergaard slides video |
||
| Use of existing data to inform and speed development of personalized medicine for CNS disorders | Chairs: William Potter Larry Alphs |
||
| Use of existing data to inform personalized CNS pharmacotherapy: What we have and what we need | William Potter slides video |
||
| The Critical Path Institute: Data drives therapeutic innovation in the neurosciences | Klaus Romero slides video |
||
| The Critical Path Institute: Impact of data sharing, regulatory successes | Diane Stephenson slides video |
||
| RWE in behavioral health: its history and its future | Kenneth Park slides |
||
| Past data mining efforts and challenges | Ni Khin slides |
||
| Future regulatory opportunities and challenges | Valentina Mantua slides |
||
| Panel Discussion | Facilitator: Larry Alphs |
||
| Remote cognitive testing: An exploration of methodological considerations in designing clinical trials | Chairs: Raeanne Moore Philip Harvey |
||
| Introduction | Philip Harvey slides |
||
| Is a composite a composite? Reflections from research on general cognitive ability | Dwight Dickinson slides |
||
| Need for equivalent in-person and remote-based cognitive tests: A perspective from pharma | Maura Furey slides |
||
| Nuts and bolts of mobile cognitive testing | Raeanne Moore slides video |
||
| Current regulatory perspectives on instrument development for remote testing | Luca Pani slides |
||
| Panel Discussion
|
Facilitators: Raeanne Moore Philip Harvey video |
||
| Neuroinflammation and CNS disorders: Construct to potential treatments | Chairs: Ronald Marcus Kemi Olugemo |
||
| Introduction | Ronald Marcus Kemi Olugemo slides |
||
| Neuroimmune mechanisms as therapeutic targets for major depressive disorder | Wayne Drevets* slides
|
||
| Anti-inflammatory trials in patients with schizophrenia: Focus on specificity of symptoms and circuits | David Goldsmith slides |
||
| Uncharted territories: Methodologies to develop new treatments to resolve inflammation | Mark Rapaport slides |
||
| Methodological considerations in clinical trials with persons with schizophrenia and bipolar disorder | Faith Dickerson slides |
||
| Are inflammatory biomarkers the new frontier in Alzheimer’s disease research? | Jacobo Mintzer slides |
||
| Panel/Regulatory Discussion | Discussants: Elena Hernandez Martinez de Lapiscina Florence Butlen-Ducuing slides |
||
| Poster Session/Reception | Poster PDFs and Abstracts | ||
17 February 2023
|
|||
|
Friday Working Group Sessions |
|||
| Assessment of Methods and Endpoints for Rapid-Acting Antidepressants-RAADs Working Group | Chairs: Christian Yavorsky Jan Sedway summary |
||
| Digital Biomarkers Decision Process Working Group | Chairs: Vikas Sharma Diane Hoffman summary slides |
||
| Working Group to Review Methodology/Collaboration Focused Grant Opportunities | Chairs: Atul Mahableshwarkar Gary Sachs summary |
||
| Unresolved problems in neuroscience: Topic 1 – Improving trial design in the precision psychiatry era | Chairs: Amir Kalali Eric Lenze |
||
| Introduction | Amir Kalali Lauren Liss slides |
||
| Precision clinical trials: How to overcome the limits of DSM | Eric Lenze slides video |
||
| Precision clinical trials: Lessons from oncology | Stephen Liu slides video |
||
| The future of trial design in the precision psychiatry era | Olusola Ajilore slides video |
||
| Using EEG to predict and monitor response to intervention in global CNS trials | Gregory Light slides video |
||
| Panel Discussion | Facilitator: Amir Kalali video |
||
| Unresolved problems in neuroscience: Topic 2 – Methodological issues in psychedelic trials | Chairs: Amir Inamdar Joyce Tsai |
||
| Introduction to psychedelics and overview of key methodological issues | Amir Inamdar slidesJoyce Tsai slides |
||
| Comparator selection in psychedelic clinical trial design | David Hellerstein slides video |
||
| Bias and blinding in psychedelic trials | Christine Moore slides video |
||
| Panel Discussion | Facilitators: Amir Inamdar Joyce Tsai video |
||
| Meeting Adjourned
|
Gary Sachs slides video |
||
| *Video not released | |||
